NEW YORK (GenomeWeb News) – Cepheid today said it has received a $3.3-million Small Business Technology Transfer grant from the National Institute of Allergy and Infectious Disease to further develop its Mycobacterium tuberculosis diagnostic.
Cepheid and academic partners at the University of Medicine and Dentistry of New Jersey have worked together to develop a PCR cartridge that can detect M. tuberculosis and predict its resistance to drugs in about one hour.
The new grant will “complement these efforts by focusing on development of sample collection devices and on development of proprietary nucleic acid dyes, quenchers, interpretive software and other technologies associated with commercial implementation of a 6-color GeneXpert system,” Cepheid said in a statement.
As GenomeWeb News reported last week, the US Food and Drug Administration said CLIA labs can use another of Cepheid’s tests, the Xpert Group B Streptococcus diagnostic, making it the first amplified molecular diagnostic using real-time PCR to receive the moderate complexity CLIA categorization. diagnostic, making it the first amplified molecular diagnostic using real-time PCR to receive the moderate complexity CLIA categorization.